CO2022002759A2 - Antagonistas de hpk1 y sus usos - Google Patents
Antagonistas de hpk1 y sus usosInfo
- Publication number
- CO2022002759A2 CO2022002759A2 CONC2022/0002759A CO2022002759A CO2022002759A2 CO 2022002759 A2 CO2022002759 A2 CO 2022002759A2 CO 2022002759 A CO2022002759 A CO 2022002759A CO 2022002759 A2 CO2022002759 A2 CO 2022002759A2
- Authority
- CO
- Colombia
- Prior art keywords
- hpk1
- hpk1 antagonists
- antagonists
- inhibition
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Abstract
La presente invención proporciona compuestos, sus composiciones, y métodos de uso de los mismos para la inhibición de HPK1, y el tratamiento de trastornos mediados por HPK1.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962900152P | 2019-09-13 | 2019-09-13 | |
US202063032070P | 2020-05-29 | 2020-05-29 | |
PCT/US2020/050524 WO2021050964A1 (en) | 2019-09-13 | 2020-09-11 | Hpk1 antagonists and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2022002759A2 true CO2022002759A2 (es) | 2022-06-21 |
Family
ID=74866704
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2022/0002759A CO2022002759A2 (es) | 2019-09-13 | 2022-03-09 | Antagonistas de hpk1 y sus usos |
Country Status (13)
Country | Link |
---|---|
US (7) | US20210078996A1 (es) |
EP (1) | EP4027995A4 (es) |
JP (1) | JP2022547719A (es) |
KR (1) | KR20220105631A (es) |
CN (1) | CN114945366A (es) |
AU (1) | AU2020347274A1 (es) |
BR (1) | BR112022004451A2 (es) |
CA (1) | CA3150108A1 (es) |
CO (1) | CO2022002759A2 (es) |
IL (1) | IL291244A (es) |
MX (1) | MX2022002877A (es) |
TW (1) | TW202126647A (es) |
WO (1) | WO2021050964A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3116347A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
TWI721623B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
WO2021050964A1 (en) * | 2019-09-13 | 2021-03-18 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
KR20230003128A (ko) | 2020-05-01 | 2023-01-05 | 화이자 인코포레이티드 | Hpk1 억제제로서의 아잘락탐 화합물 |
CN112047942B (zh) * | 2020-10-26 | 2022-01-18 | 都创(上海)医药科技股份有限公司 | 一种7-氟咪唑并[1,2-a]吡啶的合成方法 |
JP2024506909A (ja) * | 2021-02-12 | 2024-02-15 | ニンバス サターン, インコーポレイテッド | Hpk1アンタゴニスト及びその使用 |
EP4301756A1 (en) | 2021-03-05 | 2024-01-10 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
EP4313989A1 (en) * | 2021-03-29 | 2024-02-07 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
IL308121A (en) * | 2021-05-06 | 2023-12-01 | Celgene Corp | Treatment methods with n-((r)-1-(3-chloropyridin-2-yl)-2,2,2-trifluoroethyl)-2-((s)-2,6-dioxopiperidin-3-yl)-1 - oxoisoindoline-5-carboxamide |
CN115611925A (zh) * | 2021-07-14 | 2023-01-17 | 轩竹生物科技股份有限公司 | Hpk1抑制剂及其用途 |
CN117693503A (zh) | 2021-07-20 | 2024-03-12 | 阿斯利康(瑞典)有限公司 | 作为hpk1抑制剂用于治疗癌症的经取代的吡嗪-2-甲酰胺 |
WO2023015199A1 (en) * | 2021-08-03 | 2023-02-09 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
CN114230514A (zh) * | 2021-11-26 | 2022-03-25 | 渭南瑞联制药有限责任公司 | 一种合成3-氟-2-氨基异烟腈的方法 |
WO2023160577A1 (zh) * | 2022-02-23 | 2023-08-31 | 正大天晴药业集团股份有限公司 | 含有吡咯啉酮的稠合双环化合物 |
WO2023193759A1 (en) * | 2022-04-07 | 2023-10-12 | Insilico Medicine Ip Limited | Hpk1 antagonists and uses thereof |
WO2023208127A1 (zh) * | 2022-04-27 | 2023-11-02 | 南京明德新药研发有限公司 | 杂芳基取代的双环化合物及其应用 |
WO2023237085A1 (zh) * | 2022-06-10 | 2023-12-14 | 贝达药业股份有限公司 | Hpk1抑制剂及其在医药上的应用 |
WO2024015425A1 (en) | 2022-07-14 | 2024-01-18 | Fmc Corporation | Herbicidal benzoxazines |
CN114940683B (zh) * | 2022-07-26 | 2023-01-17 | 轩竹(北京)医药科技有限公司 | Hpk1抑制剂及其用途 |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2475569A (en) | 1944-02-07 | 1949-07-05 | American Cyanamid Co | Substituted pyridine compound |
US4709016A (en) | 1982-02-01 | 1987-11-24 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
US5650270A (en) | 1982-02-01 | 1997-07-22 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
US5516931A (en) | 1982-02-01 | 1996-05-14 | Northeastern University | Release tag compounds producing ketone signal groups |
US4650750A (en) | 1982-02-01 | 1987-03-17 | Giese Roger W | Method of chemical analysis employing molecular release tag compounds |
DZ3248A1 (fr) | 1999-12-10 | 2001-06-14 | Pfizer Prod Inc | Composés à base de pyrrolo[2,3-d]pyrimidine |
KR100833371B1 (ko) | 2001-04-27 | 2008-05-28 | 젠야쿠코교가부시키가이샤 | 헤테로시클릭 화합물 및 이를 유효 성분으로 하는 항종양제 |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
CN1674929B (zh) | 2002-08-14 | 2013-07-17 | 赛伦斯治疗公司 | 蛋白激酶Nβ的应用 |
AU2004228668B2 (en) | 2003-04-03 | 2011-10-27 | Park Funding, Llc | PI-3 kinase inhibitor prodrugs |
ZA200509718B (en) | 2003-05-30 | 2007-03-28 | Gemin X Biotechnologies Inc | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases |
US7129260B2 (en) * | 2003-06-02 | 2006-10-31 | Abbott Laboratories | Isoindolinone kinase inhibitors |
EP2371835A1 (en) | 2003-07-03 | 2011-10-05 | The Trustees Of The University Of Pennsylvania | Inhibition of syk kinase expression |
CN101031569B (zh) | 2004-05-13 | 2011-06-22 | 艾科斯有限公司 | 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮 |
GB0419160D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
EP2161275A1 (en) | 2005-01-19 | 2010-03-10 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
ES2657443T3 (es) | 2005-03-25 | 2018-03-05 | Gitr, Inc. | Anticuerpos anti-GITR y usos de los mismos |
US7745641B2 (en) * | 2005-04-19 | 2010-06-29 | Kyowa Hakko Kirin Co., Ltd. | Nitrogen-containing heterocyclic compound |
DK1888550T3 (da) | 2005-05-12 | 2014-09-29 | Abbvie Bahamas Ltd | Apoptosepromotorer |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
RS54271B1 (en) | 2005-07-01 | 2016-02-29 | E. R. Squibb & Sons, L.L.C. | HUMAN MONOCLONIC ANTIBODIES FOR LIGAND PROGRAMMED DEATH 1 (PD-L1) |
US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
KR20140033237A (ko) | 2005-10-07 | 2014-03-17 | 엑셀리시스, 인코포레이티드 | 포스파티딜이노시톨 3-키나아제 억제제 및 이의 사용 방법 |
CA2628283C (en) | 2005-11-01 | 2017-06-27 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
DK2348023T5 (da) | 2005-12-13 | 2017-05-15 | Incyte Holdings Corp | Heteroaryl-substituerede pyrrolo[2,3-b]pyridiner og pyrrolo[2,3-b]pyrimidiner som Janus-kinase-inhibitorer |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
NZ572812A (en) | 2006-04-26 | 2010-09-30 | Hoffmann La Roche | THIENO [3, 2-D] PYRIMIDINE Indazole DERIVATIVE USEFUL AS PI3K INHIBITOR |
SI2526771T1 (sl) | 2006-09-22 | 2017-06-30 | Pharmacyclics Llc | Inhibitorji Bruton tirozin kinaze |
EP2108642A1 (en) * | 2006-10-17 | 2009-10-14 | Kyowa Hakko Kirin Co., Ltd. | Jak inhibitor |
PT2152701E (pt) | 2007-03-12 | 2016-01-27 | Ym Biosciences Australia Pty | Compostos de fenil amino pirimidina e suas utilizações |
WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
ES2776406T3 (es) | 2007-07-12 | 2020-07-30 | Gitr Inc | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
CN101932325B (zh) | 2007-11-30 | 2014-05-28 | 新联基因公司 | Ido抑制剂 |
GB0724342D0 (en) | 2007-12-13 | 2008-01-30 | Prolysis Ltd | Anitbacterial compositions |
DK2288610T3 (en) | 2008-03-11 | 2016-11-28 | Incyte Holdings Corp | Azetidinesulfonic AND CYCLOBUTANDERIVATER AS JAK INHIBITORS |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
CN114835812A (zh) | 2008-12-09 | 2022-08-02 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
TW201100441A (en) * | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
IN2012DN01920A (es) | 2009-09-03 | 2015-07-24 | Schering Corp | |
US8722720B2 (en) | 2009-10-28 | 2014-05-13 | Newlink Genetics Corporation | Imidazole derivatives as IDO inhibitors |
AU2010329934B2 (en) | 2009-12-10 | 2015-05-14 | F. Hoffmann-La Roche Ag | Antibodies binding preferentially human CSF1R extracellular domain 4 and their use |
ME03447B (me) | 2010-03-04 | 2020-01-20 | Macrogenics Inc | Anтitela reakтivna sa b7-нз, njihovi imunološki akтivni fragmenтi i upotreba |
MX2012010014A (es) | 2010-03-05 | 2012-09-21 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
BR112012022046A2 (pt) | 2010-03-05 | 2017-02-14 | F Hoffamann-La Roche Ag | ''anticorpo,composição farmacêutica,ácido nucleico ,vetores de expressão,célula hospedeira e método para a produção de um anticorpo recombinante''. |
US8314120B2 (en) | 2010-03-30 | 2012-11-20 | Abbott Gmbh & Co. Kg | Small molecule potentiators of metabotropic glutamate receptors |
TWI651331B (zh) | 2010-05-04 | 2019-02-21 | 戊瑞治療有限公司 | 與集落刺激因子1受體(csf1r)結合之抗體類 |
MY162737A (en) | 2010-09-09 | 2017-07-14 | Pfizer | 4-1bb binding molecules |
SG10201510092QA (en) | 2010-12-09 | 2016-01-28 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
NO2694640T3 (es) | 2011-04-15 | 2018-03-17 | ||
CN103987405B (zh) | 2011-11-28 | 2017-03-29 | 默克专利股份公司 | 抗pd‑l1抗体及其用途 |
WO2013086397A1 (en) | 2011-12-08 | 2013-06-13 | Array Biopharma Inc. | Urea compounds as gka activators |
BR112014012624A2 (pt) | 2011-12-15 | 2018-10-09 | F Hoffmann-La Roche Ag | anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo |
RU2014136332A (ru) | 2012-02-06 | 2016-03-27 | Дженентек, Инк. | Композиции и способы применения ингибиторов csf1r |
AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
KR20220162819A (ko) | 2012-05-11 | 2022-12-08 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법 |
AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
SG11201501413YA (en) | 2012-08-31 | 2015-03-30 | Five Prime Therapeutics Inc | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
SG11201503396UA (en) | 2012-11-08 | 2015-05-28 | Bristol Myers Squibb Co | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNα RESPONSES |
JP6407159B2 (ja) | 2012-11-08 | 2018-10-17 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | IL−12、IL−23および/またはIFNα応答のモジュレーターとして有用なアミド置換ヘテロ環式化合物 |
US10273237B2 (en) | 2013-12-10 | 2019-04-30 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-α responses |
US9340540B2 (en) | 2014-02-28 | 2016-05-17 | Nimbus Lakshmi, Inc. | TYK2 inhibitors and uses thereof |
WO2016101119A1 (en) | 2014-12-23 | 2016-06-30 | Merck Sharp & Dohme Corp. | Fused heteroaryl derivatives as orexin receptor antagonists |
KR101660863B1 (ko) * | 2015-04-03 | 2016-09-28 | 주식회사 녹십자 | IKKε 및 TBK1 억제제로서의 7-아자인돌 또는 4,7-다이아자인돌 유도체 및 이를 포함하는 약학적 조성물 |
KR101846475B1 (ko) * | 2015-04-27 | 2018-04-09 | 주식회사 녹십자 | TNIK, IKKε 및 TBK1 억제제로서의 화합물 및 이를 포함하는 약학적 조성물 |
BR112017027241B1 (pt) * | 2015-06-25 | 2023-09-26 | University Health Network | Inibidores de hpk1 e composição farmacêutica |
CN108699077B (zh) * | 2016-01-15 | 2021-03-02 | 英安塔制药有限公司 | 作为rsv抑制剂的杂环化合物 |
WO2017147328A1 (en) * | 2016-02-23 | 2017-08-31 | Portola Pharmaceuticals, Inc. | Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9) |
AR109595A1 (es) * | 2016-09-09 | 2018-12-26 | Incyte Corp | Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1 |
CN110312711A (zh) * | 2016-10-07 | 2019-10-08 | 亚瑞克西斯制药公司 | 作为ras抑制剂的杂环化合物及其使用方法 |
US11180482B2 (en) * | 2016-11-30 | 2021-11-23 | Ariad Pharmaceuticals, Inc. | Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors |
RS63849B9 (sr) | 2016-12-16 | 2023-06-30 | Pfizer | Agonisti glp-1 receptora i njihova upotreba |
AU2018244935A1 (en) * | 2017-03-30 | 2019-08-15 | F. Hoffmann-La Roche Ag | Naphthyridines as inhibitors of HPK1 |
CN109721620B (zh) * | 2017-10-27 | 2022-05-13 | 药捷安康(南京)科技股份有限公司 | Hpk1抑制剂及其用途 |
WO2019090198A1 (en) * | 2017-11-06 | 2019-05-09 | Bristol-Myers Squibb Company | Isofuranone compounds useful as hpk1 inhibitors |
US10745388B2 (en) * | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
US10752635B2 (en) * | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
US20200038378A1 (en) | 2018-04-01 | 2020-02-06 | Arvinas Operations, Inc. | Brm targeting compounds and associated methods of use |
US20210361637A1 (en) | 2018-10-29 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof |
WO2021050964A1 (en) * | 2019-09-13 | 2021-03-18 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
EP4168411A1 (en) * | 2020-06-22 | 2023-04-26 | PMV Pharmaceuticals, Inc. | Methods and compounds for restoring mutant p53 function |
-
2020
- 2020-09-11 WO PCT/US2020/050524 patent/WO2021050964A1/en unknown
- 2020-09-11 MX MX2022002877A patent/MX2022002877A/es unknown
- 2020-09-11 KR KR1020227012023A patent/KR20220105631A/ko active Search and Examination
- 2020-09-11 US US17/018,591 patent/US20210078996A1/en active Pending
- 2020-09-11 CA CA3150108A patent/CA3150108A1/en active Pending
- 2020-09-11 BR BR112022004451A patent/BR112022004451A2/pt unknown
- 2020-09-11 EP EP20862150.8A patent/EP4027995A4/en active Pending
- 2020-09-11 CN CN202080072523.0A patent/CN114945366A/zh active Pending
- 2020-09-11 AU AU2020347274A patent/AU2020347274A1/en active Pending
- 2020-09-11 JP JP2022516403A patent/JP2022547719A/ja active Pending
- 2020-09-14 US US17/020,050 patent/US11028085B2/en active Active
- 2020-09-14 US US17/020,013 patent/US11078201B2/en active Active
- 2020-09-14 US US17/020,173 patent/US11021481B2/en active Active
- 2020-09-14 TW TW109131550A patent/TW202126647A/zh unknown
- 2020-09-14 US US17/020,122 patent/US11034694B2/en active Active
-
2021
- 2021-07-12 US US17/305,632 patent/US11548890B1/en active Active
-
2022
- 2022-03-09 IL IL291244A patent/IL291244A/en unknown
- 2022-03-09 CO CONC2022/0002759A patent/CO2022002759A2/es unknown
-
2023
- 2023-07-11 US US18/350,536 patent/US20240025898A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11028085B2 (en) | 2021-06-08 |
US20240025898A1 (en) | 2024-01-25 |
US11078201B2 (en) | 2021-08-03 |
JP2022547719A (ja) | 2022-11-15 |
IL291244A (en) | 2022-05-01 |
EP4027995A1 (en) | 2022-07-20 |
US11548890B1 (en) | 2023-01-10 |
US20210087190A1 (en) | 2021-03-25 |
US20210078996A1 (en) | 2021-03-18 |
EP4027995A4 (en) | 2023-08-23 |
WO2021050964A1 (en) | 2021-03-18 |
CN114945366A (zh) | 2022-08-26 |
US20210078997A1 (en) | 2021-03-18 |
US20210078998A1 (en) | 2021-03-18 |
AU2020347274A1 (en) | 2022-03-31 |
US20210087189A1 (en) | 2021-03-25 |
US11034694B2 (en) | 2021-06-15 |
US11021481B2 (en) | 2021-06-01 |
KR20220105631A (ko) | 2022-07-27 |
BR112022004451A2 (pt) | 2022-06-21 |
CA3150108A1 (en) | 2021-03-18 |
MX2022002877A (es) | 2022-08-08 |
TW202126647A (zh) | 2021-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2022002759A2 (es) | Antagonistas de hpk1 y sus usos | |
CL2021003191A1 (es) | Inhibidores de tead y usos de los mismos | |
CL2021003190A1 (es) | Inhibidores de tead y usos de los mismos | |
CO2021007068A2 (es) | Degradadores de irak y usos de los mismos | |
CL2019003627A1 (es) | Anticuerpos anti-pd-1 y sus usos. (solicitud divisional 201900628) | |
UY38076A (es) | Derivados de tetrahidroquinazolina útiles como agentes anticáncer | |
UY38070A (es) | Derivados de quinazolina y piridopirimidina sustituidos útiles como agentes anticáncer | |
ECSP19003773A (es) | Compuestos heterocíclicos como inmunomoduladores | |
MX2023004593A (es) | Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos. | |
CO2022008406A2 (es) | Degradadores de irak y usos de los mismos | |
ECSP16067303A (es) | Heteroarilos y usos de estos | |
DOP2018000268A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
CO2021013339A2 (es) | Degradadores de stat y usos de los mismos | |
UY38403A (es) | Moduladores de la alfa-1 antitripsina | |
CR20190071A (es) | Compuestos, composiciones y métodos para el tratamiento de enfermedades | |
CL2018000375A1 (es) | 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1. | |
ECSP17023281A (es) | Inhibidores de mk2 y sus usos | |
CO2020015747A2 (es) | Analogos de rapamicina y usos de los mismos | |
CL2020000375A1 (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre. | |
ECSP17074645A (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa | |
CL2016002084A1 (es) | Compuestos derivados de ciclopentano 1,2 substituidos como antagonistas del receptor de orexina. | |
CO2022008662A2 (es) | Degradadores de smarca y usos de los mismos | |
CY1124338T1 (el) | Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων | |
CL2018001252A1 (es) | Métodos para tratar esclerosis múltiple usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton | |
CL2018003121A1 (es) | Inhibidores del potenciador del homólogo zeste 2. |